Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 17/10/2018
SIETES contiene 92567 citas

 
 
 1 a 20 de 28 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Joseph A. FDA approves country’s first medicine made from marijuana. STAT Daily Recap 2018:2. [Ref.ID 102664]
2. Cita con resumen
Joseph A. Panel recommends FDA approval of epilepsy drug derived from marijuana. DIA Daily 2018:1. [Ref.ID 102518]
3.Tiene citas relacionadas Cita con resumen
Varadkar S. Cannabidiol for drop seizures in Lennox-Gastaut syndrome. Lancet 2018;391:1006-7. [Ref.ID 102474]
4.Tiene citas relacionadas Cita con resumen
Thiele EA, French ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, Lyons PD, Taylor A, Roberts C, Sommerville K, on behalf of the GWPCARE4 Study Group. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2018;391:24 de enero. [Ref.ID 102450]
5.
Whitlock J. Cannabis-derived drug granted priority review. San Diego Business Journal 2018:2 de enero. [Ref.ID 102441]
6.Tiene citas relacionadas Cita con resumen
Berkovic SF. Cannabinoids for epilepsy — Real data, at last. N Engl J Med 2017;376:2075-6. [Ref.ID 101596]
7.Tiene citas relacionadas Cita con resumen
Devinsky O, Cross JH, Laux L, Marsh E, Nabbout R, Scheffer IE, Thiele EA, Wright S, for the Cannabidiol in Dravet Syndrome Study Group. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 2017;376:2011-20. [Ref.ID 101595]
8. Cita con resumen
Virji S. Sativex disappoints in multiple sclerosis pain trial. Scrip 2008;3353:18. [Ref.ID 82683]
9. Cita con resumen
Anónimo. GW Pharmaceuticals welcomes MHRA move to publish opinion on Sativex. Scrip 2008;3323/3324:4. [Ref.ID 81913]
10. Cita con resumen
Anónimo. GW's Sativex approved in Canada for second indication. Scrip 2007;3285:22. [Ref.ID 80727]
11. Cita con resumen
Anónimo. GW Pharmaceuticals plans US Sativex Phase II/III trial in cancer pain. Scrip 2007;3254:25. [Ref.ID 79942]
12. Cita con resumen
Anónimo. GW Pharmaceuticals secures US Sativex partner. Scrip 2007;3234:6. [Ref.ID 79248]
13. Cita con resumen
Anónimo. GW upbeat with new EU filing for Sativex. Scrip 2006;3190:19. [Ref.ID 78048]
14. Cita con resumen
Anónimo. GW Pharma spending rises on cannabis drug trials. Scrip 2006;3170:8. [Ref.ID 77324]
15. Cita con resumen
Anónimo. More disappointment for GW's Sativex. Scrip 2006;3141:19. [Ref.ID 76428]
16. Cita con resumen
Anónimo. GW has year of progress as Sativex launched. Scrip 2006;3126:11. [Ref.ID 76084]
17. Cita con resumen
Anónimo. GW raises funds for US Sativex trials. Scrip 2006;3121:11. [Ref.ID 75881]
18. Cita con resumen
Anónimo. GW Pharmaceuticals strike European Sativex deal. Scrip 2005;3115:11. [Ref.ID 75697]
19. Cita con resumen
Anónimo. Importing Sativex no guarantee of approval. Scrip 2005;3109:8. [Ref.ID 75475]
20. Cita con resumen
Anónimo. Sativex made available in Spain, and hopes rise for use in UK. Scrip 2005;3108:4. [Ref.ID 75449]
Seleccionar todas
 
 1 a 20 de 28 siguiente >>